(Q53191334)

English

Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.

scientific article published on 16 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

prostate cancer

1 reference

based on heuristic

inferred from title

Peter Bartenstein

11

object named as

Peter Bartenstein

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

8

object named as

Paul Cumming

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

12

object named as

Marcus Hacker

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Christopher Übleis

3

object named as

Christopher Ubleis

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

1

object named as

Vera Graute

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Markus Hartenbach

5

object named as

Markus Hartenbach

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Nathalie L Jansen

2

object named as

Nathalie Jansen

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

author name string

Michael Seitz

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Michael Karl Scherr

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Sven Thieme

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Katharina Klanke

9

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Reinhold Tiling

10

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

publication date

16 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

39

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

271-282

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Critical analysis of prostate-specific antigen doubling time calculation methodology

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Fluorocholine PET/CT in patients with prostate cancer: initial experience

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22086143

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22086143

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates

1 reference

https://pubmed.ncbi.nlm.nih.gov/22086143

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-011-1970-2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53191334&oldid=2212024902"